48.10 0.00 (0.00%)
After hours: 4:17PM EDT
|Bid||48.10 x 800|
|Ask||48.14 x 2200|
|Day's Range||47.88 - 48.65|
|52 Week Range||41.23 - 52.83|
|Beta (3Y Monthly)||0.83|
|PE Ratio (TTM)||19.54|
|Forward Dividend & Yield||1.25 (2.39%)|
|1y Target Est||53.90|
Learn how the marriage of science and technology is changing the world of medicine and creating some of the largest multinational biotechnology corporations.
Share price of Novo Nordisk (NVO) has increased year to date on strong presence in the Diabetes Care market and a solid pipeline.
Gilead (GILD) collaborates with data-driven company, Insitro, to harness the power of computers to discover and develop therapies for treating NASH (fatty liver).
in their efforts to help combat liver disease. The two companies said they will collaborate on clinical trials for medications for treating nonalcoholic steatohepatitis (NASH). "The intended clinical trial will be a proof of concept study," according to a press release from Gilead.
Novo Nordisk and Gilead Sciences will join forces on a clinical trial combining drugs from the two pharmaceutical firms to treat a progressive fatty liver disease known as NASH. The clinical trial will be a study combining Novo Nordisk's semaglutide drug and Gilead's cilofexor and firsocostat for treatment of patients with Nonalcoholic steatohepatitis (NASH), Novo Nordisk, best known for its diabetes drugs, said on Friday.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Building up an investment case requires looking at a stock holistically. Today I've chosen to put the spotlight on N...
Sangamo (SGMO) and partner Pfizer announce encouraging data from a phase I/II study evaluating their gene therapy candidate for treating hemophilia A.
Is Adobe Inc. (NASDAQ:ADBE) a healthy stock for your portfolio? Money managers are becoming more confident. The number of long hedge fund bets moved up by 5 recently. Our calculations also showed that ADBE is among the 30 most popular stocks among hedge funds, ranking 16th. Hedge fund sentiment towards Adobe is currently at an […]
Without insulin, diabetes patients will die, and many simply cannot afford to keep living. Warning! GuruFocus has detected 5 Warning Sign with NVO. The finger-pointing rages between insulin manufacturers and pharmacy benefit managers, but the truth may be that neither of them are responsible.
It was a rough fourth quarter for many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing the S&P by more […]
If you are interested in cashing in on Novo Nordisk A/S's (CPH:NOVO B) upcoming dividend of ø5.15 per share, you only have 4 days left to buy the shares beforeRead More...
Eli Lilly (LLY) plans to launch a cheaper version of its popular insulin, Humalog amid increasing pressure to lower drug costs.
PLAINSBORO, N.J., March 1, 2019 /PRNewswire/ -- Novo Nordisk today announced that it recently submitted label updates to the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for Fiasp® (insulin aspart injection) 100 u/mL, seeking approval for use as a new mealtime insulin for children and adolescents with type 1 diabetes. Fiasp® is currently approved to control high blood sugar in adults with diabetes. Managing diabetes around mealtimes can be hard1, with parents of young children with type 1 diabetes reporting that this was one of the most problematic areas2.
Ophthotech (OPHT) reports wider-than-expected loss in the fourth quarter. It boosts gene therapy pipeline through new agreements and acquisitions.
Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).
Novo Nordisk (NVO) clinches the FDA approval for its biologics license application in favor of Esperoct to treat adults and children suffering haemophilia A.
Seattle Genetics' (SGEN) partner, Takeda Pharmaceutical receives EC approval for Adcetris in combination with AVD to treat adults with previously untreated CD30+ stage IV cHL.